A carregar cotações...
Previsão
Não temos dados de analistas para esta empresa.
Notícias Ir para o feed de notícias
Ambu A-S expects increase in revenue and profit in latest quarter
Ambu A-S will release its quarterly results on 5 November 2026. Two analysts on average expect earnings per share of 0.862 DKK, up from 0.430 DKK in the year-ago quarter. Six analysts forecast revenue to rise 13.54 percent to around 1.66 billion DKK. For the past fiscal year, the analyst consensus is 2.40 DKK earnings per share and revenue of 6.44 billion DKK. » Mais em finanzen.net
Ambu share falls 15% after slightly missed quarter
Ambu narrowly missed consensus expectations in the third quarter with EPS of $0.62 and revenue of $1.64bn, after which the stock fell 15.15% to $66.35. Organic revenue growth was 10.3%, driven by Endoscopy Solutions (+16%), and reported EBIT rose to 13.5%. Management raised the full-year forecast for organic growth to around 10% but warned of short-term margin pressures from higher selling expenses, currency and duties costs, and upcoming duty refunds that are expected to support the next quarter. » Mais em de.investing.com
Ambu forecasts significant quarterly growth in EPS and revenue
Ambu will publish results on 26 August 2026 for the quarter ended 30 June 2026. Analysts on average expect EPS of 0.617 DKK, up 34.13% from 0.460 DKK a year earlier, and revenue of 1.65 billion DKK on average (+9.43% versus 1.51 billion DKK). For the current fiscal year, consensus estimates are 2.32 DKK earnings per share (previous year 2.29 DKK) and annual revenue of 6.47 billion DKK (previous year 6.04 billion DKK). » Mais em finanzen.net
Dividendos históricos Dividendos
Todos os indicadores de dividendos Todos os indicadoresDados financeiros da empresa
| (EUR) | junho de 2026 | YoY |
|---|---|---|
| Receitas | 219,41 mi | 8,62% |
| Ganho bruto | 130,44 mi | 9,72% |
| Ganho líquido | 20,87 mi | 26,59% |
| EBITDA | 42,95 mi | 20,45% |
Dados fundamentais
| Métrica | Valor |
|---|---|
Capitalização bolsista | € 2,46 bi |
Número de ações | 232,24 mi |
Máximo/mínimo de 52 semanas | € 14,58 - € 7,53 |
Rentabilidade de dividendos | 0,52% |
Dividendos TTM | € 0,0549 |
Beta | 1,38 |
PER (PE Ratio) | 41,52 |
PEG (PEG Ratio) | 0,98 |
P/VC (PB Ratio) | 3,43 |
P/V (PS Ratio) | 2,95 |
Perfil da empresa
Ambu A/S entwickelt, produziert und vertreibt medizinische Geräte für Krankenhäuser, Kliniken und Rettungsdienste weltweit. Das Unternehmen bietet Gesundheitslösungen in den Bereichen Visualisierung, Anästhesie, Patientenüberwachung und Diagnostik. Das Unternehmen bietet Produkte für die Endoskopie, wie Bronchoskope und Monitore, und Produkte für die Neurologie, wie EEG- und EMG-Elektroden, EMG-geführte Injektionen und intraoperative Überwachungsprodukte. Darüber hinaus bietet das Unternehmen Produkte für die Kardiologie, bestehend aus EKG-Elektroden, sowie Produkte für das Atemwegsmanagement und die Anästhesie, wie Bronchoskope, Videolaryngoskope, doppel- und einlumige Tuben, endobronchiale Blocker, Kehlkopf- und Gesichtsmasken, Beatmungsbeutel und Wiederbelebungsgeräte. Darüber hinaus bietet das Unternehmen Befreiungsmanschetten, Kopf-Immobilizer, CPR-Atembarrieren und Übungspuppen an. Ambu A/S wurde 1937 gegründet und hat seinen Hauptsitz in Ballerup, Dänemark.
| Nome | Ambu |
| CEO | Britt Meelby Jensen |
| Sede | Ballerup,
cr Dinamarca |
| Site | |
| Setor | Cuidados de saúde |
| Indústria | Cuidados de saúde: equipamentos e produtos |
| Entrada em bolsa | 11/02/2004 |
| Colaboradores | 5.200 |
Análise aprofundada
Símbolos de ticker
| Bolsa | Símbolo |
|---|---|
Nasdaq Copenhagen | AMBU-B.CO |
Pnk | AMBFF |
Copenhagen | AMBU B.CO |
Frankfurt | 547A.F |
Düsseldorf | 547A.DU |
London | 0MJF.L |
München | 547A.MU |